Sen-Jam Pharmaceutical

Here is a must read for anyone who consumes #alcohol and has an interest in #health and #longevity, https://lnkd.in/geKt9iGQ

We were recently independently reviewed by Alts.co, https://lnkd.in/emzM4v3b #pharmaceutical #innovation #wellbeing Wefunder #entrepreneurship #venturecapital

???This is your last chance to join our mission at our most favorable terms. Tonight at midnight these special incentives sunset for good. Don't delay! We're transforming healthcare, and your opportunity to be a part of history awaits... https://bit.ly/31mYAcD to learn more #inflammation #senjampharma #goodkarmapharma

???3 DAYS LEFT! Don't miss Sen-Jam Pharmaceutical's premier investor incentives. We're transforming healthcare, and your opportunity awaits. https://bit.ly/31mYAcD to learn more. #inflammation #senjampharma #goodkarmapharma

We are excited to announce our latest Partnership with Destum Partners, Inc to Source Strategic Partnerships for SJP-001 & SJP-00C.

?? Tomorrow at 2 PM EST: Sen-Jam’s 2025 Growth Webinar Get insider insights on: ? JPMorgan Conference Update ? PAIR Technology breakthroughs ? Promising SJP-002C trial results ? Advances in SJP-001 & new patents ? Don’t miss this chance to hear from our leadership team! ?? Register Now https://bit.ly/4jnmlo5 #inflammation #goodkarmapharma #senjampharma #webinars

? Big News for Sen-Jam Pharmaceutical! ? Our groundbreaking hangover therapeutic, SJP-001, has been spotlighted in a newly published paper linking frequent alcohol consumption and hangovers to chronic inflammation and heightened cancer risks. Aligning with the recent Advisory issued by the US Surgeon General. With the first FDA-approved hangover remedy in development, we’re tackling both immediate symptoms and long-term health risks. ???? Backed by strong clinical data and a $6B market opportunity by 2030, SJP-001 is positioned to make waves in public health and investor portfolios alike. Learn more about this transformative opportunity: https://lnkd.in/g3e45biD #Innovation #Healthcare #InvestInTheFuture #senjampharma #inflammation

?? Important Update: Phase 2 Clinical Trial Results for SJP-002C Validates our PAIR Technology Platform Promising safety data and efficacy signals for upper respiratory infections, supporting our innovative PAIR platform tech Read update?? https://lnkd.in/gxnNqdG4 #inflammation #senjampharma #goodkarmapharma #clinicaltrials

Exciting news today: Sen-Jam Pharmaceutical has entered a financial & strategic investment agreement with 5 Horizons Capital, a premier investment firm known for its expertise in identifying and supporting disruptive healthcare innovations. You can read more about this here: https://lnkd.in/g7_aiKyM #inflammation Aaron Ray Jim Iversen #goodkarmapharma

?? Transforming Inflammatory Care ?? Sen-Jam Pharmaceutical’s PAIR Technology is rewriting the rules of anti-inflammatory medicine. Fresh from the JPMorgan Healthcare Conference and backed by Phase 2 clinical trial success, our revolutionary platform promises to address systemic inflammation in ways previously thought impossible. Join us in pioneering a new era of healthspan preservation and see why PAIR is positioned to be the fifth transformative moment in anti-inflammatory medicine. read here: https://lnkd.in/gfmrnz6N ?? Don’t miss our exclusive webinar on January 29 at 2 PM EST, where we’ll share insights from our latest breakthroughs. ?? Register here: https://bit.ly/4jnmlo5 Be part of the revolution. ?? hashtag #senjampharma hashtag #JPM2025 hashtag #inflammation